Operational AI use cases for regulated life sciences.

PROBLEM

Pharmacovigilance teams manage growing volumes of unstructured documents including published literature, aggregate safety reports, Health Authority correspondence, and clinical case files that require expert review before any safety determination can be made. Reading, extracting the safety-relevant content, and drafting a structured response is time-consuming, inconsistent across reviewers, and difficult to scale as submission timelines compress.

AI ASSISTED SYSTEM

• An AI-assisted document summarization tool addresses this across several connected workflows.
• Manually uploaded journal articles are processed to extract safety-relevant content, specifically any reported adverse events associated with the company’s medication, and structured into a summary ready for Health Authority submission.
• The tool surfaces everything flagged as safety-significant for medical review, with the source passage cited alongside each finding.
• The same capability extends to aggregate reports, leadership briefings, and other document types.
• When a Health Authority issues a formal question requiring a response across a large case set, typically 50 to 100 individual cases each running several pages, the tool ingests the full case file, extracts relevant content, and generates a structured first-draft response.
• The reviewer edits, validates, and approves. All summaries are traceable to source documents and every extraction decision is logged for regulatory inspection readiness.
• The document types and workflows addressed can be extended to any summarization need across the R&D organization.

PROBLEM

Safety databases contain structured data, along with large volumes of unstructured narrative text that structured data alone does not capture. Potential signals embedded in adverse event narratives are frequently identified late through manual review processes that do not scale.

AI ASSISTED SYSTEM

• An NLP agent systematically processes incoming case narratives, extracts clinically relevant patterns, and cross-references findings against internal safety data and published literature.
• Candidate signals are flagged for medical review with a structured evidence summary.
• The agent organizes the case; the physician evaluates it.
• No signal determination is automated.
• Full traceability from source narrative to flagged finding is maintained for regulatory inspection readiness.
• The same pattern applies wherever narrative text contains safety-relevant information that structured fields do not capture.

PROBLEM

Individual deviations are reviewed, coded, and closed. The patterns across them, by site, investigator, protocol section, or enrollment phase, are rarely analyzed with the frequency or granularity that early risk identification requires. By the time a systemic issue surfaces through standard review cycles, corrective action is already late.

AI ASSISTED SYSTEM

• An AI-assisted detection model aggregates deviation records across the trial portfolio, applies pattern recognition across site and temporal dimensions, and generates structured anomaly alerts for operational review.
• The model does not make decisions; it changes the speed and specificity of human review.
• Site performance briefs give clinical operations leads a structured starting point for investigation.
• This pattern extends to any clinical operations dataset where pattern detection across time and site dimensions would change the quality or speed of operational response.

PROBLEM

Regulatory teams responsible for global submission portfolios face a continuous monitoring burden: tracking label updates, agency guidance, and competitive intelligence across multiple markets and therapeutic areas. Skilled professionals spend time on information aggregation rather than analysis.

AI ASSISTED SYSTEM

• A multi-step regulatory intelligence agent monitors configured agency publication channels, classifies updates by type and therapeutic area, assesses potential downstream impact on the submission portfolio, and delivers structured summaries on a defined cadence.
• The agent surfaces what changed, where it applies, and what needs human judgment.
• It builds an auditable record of regulatory changes reviewed and their disposition.
• The same monitoring and classification pattern can be configured for any combination of markets, agency types, and submission portfolios relevant to the organization.

PROBLEM

Clinical study reports require accurate, structured patient narratives for serious adverse events, deaths, and other significant outcomes. Writing and reviewing these narratives is labor-intensive and creates timeline pressure at study close.

AI ASSISTED SYSTEM

• An AI-assisted medical writing agent ingests source data including case report forms, laboratory data, and investigator comments, and generates a structured draft narrative conforming to defined format requirements. A medical writer reviews, edits, and approves.
• The system eliminates the blank-page problem; it does not replace clinical judgment.
• Output is traceable to source data and validation documentation supports use in a GxP medical writing workflow.
• The same drafting pattern applies to other structured medical writing tasks across the R&D organization where source data is well-defined and format requirements are consistent.